Pemetrexed beneficial in NSCLC, but only for certain types

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1640, 2008-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus pemetrexed promising in advanced NSCLC

Inpharma, Vol. 1, Iss. 1460, 2004-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Maintenance pemetrexed too costly for NSCLC in China

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 671, 2013-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Less toxicity with pemetrexed spells savings in NSCLC

Inpharma, Vol. 1, Iss. 1413, 2003-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Second-line pemetrexed, docetaxel similarly effective for NSCLC

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

NICE OKs arthritis therapies, not pemetrexed for NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 536, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite